CompletedHealthcare2 November 2026

Biossil Labs Inc. to acquire Theriva Biologics' ribaxamase and SYN-006 assets

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
Biossil Labs Inc.
Target
Theriva Biologics ribaxamase and SYN-006 assets
Deal value
USD 350,000
Announced
2 November 2026
Status
Completed
Sector
Healthcare
Country
United States
Consideration
cash, earn-out
What we know

Theriva Biologics, Inc. (NYSE American: TOVX) sold its ribaxamase program to Biossil Labs Inc., a corporation organized under the laws of Canada, under an Asset Purchase and Sale Agreement dated October 30, 2026. The purchased assets are those exclusively relating to SYN-004 (ribaxamase), Theriva's oral β-lactamase product candidate, including improvements, modifications and reformulations such as SYN-007, plus certain assets exclusively related to SYN-006, its carbapenemase product candidate. They include the related patents, specified contracts, regulatory filings and approvals (including an investigational new drug application), inventory, materials and data. Theriva also granted Biossil a non-exclusive, perpetual, worldwide, royalty-free license under certain other company intellectual property, solely to the extent needed to exploit the products.

The deal signed and closed on the same day, October 30, 2026. Theriva disclosed it in a Form 8-K that cites a press release dated November 2, 2026 announcing the agreement. Biossil paid an upfront $350,000 at closing, which is non-refundable. Theriva is also eligible for up to $3 million in regulatory milestones (first FDA approval and first European Medicines Agency marketing authorization of any product) and up to $88 million in sales milestones tied to cumulative worldwide net sales. It may also receive a low-single-digit percentage royalty on worldwide net sales, capped at $250 million, and a low-double-digit percentage of certain license consideration Biossil or another selling party receives, which is not subject to the royalty cap.

Biossil assumed only specified liabilities, generally those arising after closing from its ownership or exploitation of the assets and its post-closing obligations under assumed contracts. Theriva kept all other liabilities, along with all cash, contracts Biossil did not assume, and intellectual property outside the purchased set. Biossil has sole control over development and commercialization and agreed to use commercially reasonable efforts to develop and obtain regulatory approval for at least one product.

A same-day amendment with PREV ABR LLC changes what Theriva owes PREV under their 2012 asset purchase agreement. Theriva paid PREV $140,000 at closing. It will pay PREV 50% of regulatory and sales milestones, 33⅓% of royalties and 50% of other consideration, including license payments, subject to an aggregate cap of $13.0 million. Under the Biossil agreement, Theriva provides transition assistance for 120 days after closing. Biossil may offset certain finally determined indemnification amounts against payments owed to Theriva, other than the upfront payment, and may not assign the purchased assets unless the assignee assumes its payment obligations. New York law governs, and disputes go to confidential arbitration in New York, New York.

The archive tags include an earn-out. Compare completion cash, deferred payments and earn-outs before treating a headline amount as proceeds. Check the underlying announcement for the actual conditions; tags are not a complete payment schedule.

Deal timeline

1 update
  1. CompletedClosed

    Biossil Labs Inc. completes acquisition of Theriva Biologics, Inc.

    Item 1.01. Entry into a Material Definitive Agreement. On October 30, 2026 (the “Effective Date”), Theriva Biologics, Inc. (the “Company”) entered into an Asset Purchase and Sale Agreement (the “Purchase Agreement”) with Biossil Labs Inc., a corporation organized under the laws of Canada (the “Biossil”), pursuant to which the Company sold to Biossil, and Biossil purchased from the Company, the Com

    Source

For business owners

What would selling your own business involve?

Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.

Guides are free to read. Free tools require email access; indicative results are not professional advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

10 November 2026Firm intentionHealthcare

BioNTech US Inc. to acquire a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc.

BioNTech US Inc. has agreed to buy a Rare Pediatric Disease Priority Review Voucher from Scholar Rock Inc. for $205 million in cash. Scholar Rock Inc. is a wholly owned…

Buyer
BioNTech US Inc.
Target
Rare Pediatric Disease Priority Review Voucher of Scholar Rock Inc.
Deal value
USD 205,000,000
Deal type
asset sale

Buyer history

Biossil Labs Inc.

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive